Drugs Containing Excipient (Inactive Ingredient) MEGLUMINE

Branded drugs containing MEGLUMINE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
L Perrigo Company	GOOD SENSE LANSOPRAZOLE	lansoprazole	0113-0116	MEGLUMINE
L Perrigo Company	PREVACID 24 HR	lansoprazole	0113-6117	MEGLUMINE
L Perrigo Company	BASIC CARE LANSOPRAZOLE	lansoprazole	0113-7116	MEGLUMINE
Azurity Pharmaceuticals Inc	WIDAPLIK	telmisartan, amlodipine and indapamide	24338-001	MEGLUMINE	2028-06-05
Azurity Pharmaceuticals Inc	XIFYRM	meloxicam	24338-153	MEGLUMINE
Topco Associates LLC	TOPCARE LANSOPRAZOLE	lansoprazole	36800-295	MEGLUMINE

Generic drugs containing MEGLUMINE excipient

Company	Ingredient	NDC	Excipient
L Perrigo Company	lansoprazole	0113-0116	MEGLUMINE
L Perrigo Company	lansoprazole	0113-0117	MEGLUMINE
L Perrigo Company	esomeprazole	0113-0651	MEGLUMINE
L Perrigo Company	esomeprazole	0113-0732	MEGLUMINE
L Perrigo Company	esomeprazole	0113-0898	MEGLUMINE
L. Perrigo Company	lansoprazole	0113-1114	MEGLUMINE

Market Dynamics and Financial Trajectory for Meglumine

Last updated: February 23, 2026

What Is Meglumine and Its Role in the Pharmaceutical Industry?

Meglumine, also known as N,N-dimethylglucamine, is a hydrophilic organic compound used as a carrier solvent, stabilizer, and pH adjuster in pharmaceutical formulations. It is a derivative of glucose and is commonly incorporated in contrast agents for diagnostic imaging, notably in MRI procedures.

Market Size and Growth Drivers

Current Market Valuation

As of 2023, the global meglumine market is valued at approximately USD 500 million. The segment related to contrast agents constitutes the bulk, accounting for roughly 75% of revenues.

Growth Rate

The compound is projected to grow at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030. This growth surpasses the overall pharmaceutical excipients market, which is expected to expand at 3.4% over the same period.

Key Drivers

1. Ascendancy of MRI Diagnostics: The increasing adoption of MRI scans worldwide boosts demand for contrast agents containing meglumine. The expanding healthcare infrastructure in emerging markets amplifies this effect.

2. Technological Innovations in Contrast Agents: Advances in contrast media formulations that optimize safety and efficacy enhance meglumine's application scope. The ongoing development of new imaging modalities increases compatibility needs.

3. Regulatory Approvals and Reimbursements: Regulatory approvals in major markets, coupled with favorable reimbursement policies, expand access to contrast agents, indirectly supporting meglumine sales.

4. COVID-19 Pandemic Impact: The pandemic prompted a surge in diagnostic imaging, ensuring continuity and steady demand for contrast agents during 2020-2022, with a subsequent stabilization period.

Market Segmentation and Geographic Distribution

Segment	Share (%)	Key Factors
Application in MRI contrast agents	75%	Dominates due to widespread use in diagnostic imaging.
Other pharmaceutical applications	15%	Includes pH buffers, delivery systems, and stabilizers.
Non-pharmaceutical uses	10%	Limited but includes research reagents.

Geographically, North America holds approximately 45% market share, driven by high healthcare expenditure and established medical infrastructure. Europe accounts for 25%, with leveraged regulatory pathways supporting growth. Asia-Pacific exhibits the highest CAGR at 6%, attributed to rapid healthcare development and population growth.

Competitive Landscape

Major players include:

• BASF SE: Leading supplier with integrated manufacturing facilities.
• Jubilant Life Sciences: Noted for manufacturing high-quality excipients.
• Fresenius Kabi: Provides contrast media formulations using meglumine.
• Seikagaku Corporation: Focuses on specialized biomedical products.

Barriers to entry involve strict regulatory compliance, large-scale manufacturing capabilities, and established distribution channels.

Regulatory Environment and Impact

FDA and EMA approvals facilitate commercialization in Western markets. The FDA categories meglumine-containing contrast agents as Class II devices, requiring clearance but with manageable regulatory pathways. In emerging markets, regulatory harmonization efforts influence market access timelines.

Financial Trajectory and Investment Outlook

Revenue Projections

• Revenue is expected to reach USD 700 million by 2030, driven by increased demand for MRI contrast agents and pharmaceutical applications.
• The segment dedicated solely to contrast agents will see the most substantial growth, with CAGR exceeding 5%.

Profitability and Investments

• Companies investing in process optimization and new manufacturing technologies aim to reduce production costs by circa 10-15% by 2025.
• R&D for novel meglumine-based formulations involves investments totaling approximately USD 50-60 million annually, reflecting the strategic importance of innovation.

Risks and Challenges

• Stringent regulatory requirements could delay product launches or expansion.
• Fluctuations in raw material prices, notably glucose derivatives, impact margins.
• Market saturation in developed regions may limit growth prospects, shifting attention to emerging markets.

Key Takeaways

• The global meglumine market is expanding, with particular strength in MRI contrast agents.
• Growth is fueled by healthcare infrastructure investments, technological innovations, and regulatory support.
• North America leads the market, but Asia-Pacific presents the highest growth rate.
• Competition centers on manufacturing scale, regulatory expertise, and R&D capabilities.
• Strategic investments align toward cost reduction, innovation, and expansion into emerging markets.

Frequently Asked Questions

1. What is the primary application of meglumine in medicine? It mainly functions as a component in MRI contrast agents to enhance imaging quality.

2. How does regulatory approval influence market growth? Approvals in major markets facilitate commercialization, expand access, and enhance profitability.

3. What are the main risks for investors in the meglumine market? Regulatory delays, raw material price volatility, and market saturation are key risks.

4. Which regions offer the most growth potential? Asia-Pacific offers the highest CAGR, driven by expanding healthcare infrastructure.

5. What future innovations could impact the meglumine market? Development of safer, more effective contrast agents and alternative excipient formulations.

References

[1] Frost & Sullivan. (2022). Global pharmaceutical excipients market analysis.
[2] MarketsandMarkets. (2023). Contrast media agents market forecasts.
[3] U.S. Food and Drug Administration. (2022). Regulatory pathway for MRI contrast agents.
[4] Research and Markets. (2023). Asia-Pacific healthcare industry analysis.